Castle Biosciences Study Shows High Demand for Molecular Testing in Atopic Dermatitis Treatment
Event summary
- A new study published in Dermatology and Therapy found that 55% of atopic dermatitis patients modified their treatment due to lack of efficacy.
- 83% of respondents expressed interest in molecular testing to guide treatment selection, rising to 94% among those open to new systemic therapies.
- The study included 43 patients and caregivers surveyed at the 2024 National Eczema Association Eczema Expo.
- Castle Biosciences' AdvanceAD-Tx test aims to personalize systemic therapy decisions based on individual disease biology.
The big picture
The study underscores the growing demand for personalized treatment approaches in dermatology, particularly for chronic conditions like atopic dermatitis. Castle Biosciences is positioning AdvanceAD-Tx as a key player in this shift, leveraging molecular diagnostics to improve treatment outcomes. The broader trend toward precision medicine in dermatology is gaining momentum, with diagnostic tools increasingly guiding therapeutic decisions.
What we're watching
- Adoption Pace
- The pace at which AdvanceAD-Tx gains clinical adoption will determine its market impact.
- Competitive Positioning
- Whether Castle Biosciences can sustain differentiation in the growing molecular diagnostics space.
- Regulatory Acceptance
- How regulatory bodies will view the clinical validation data supporting AdvanceAD-Tx.
Related topics